Epcoritamab Demonstrates Complete Responses at 2 Years in R/R LBCL

News
Video

Results from the EPCORE NHL-1 trial shared at the 2025 ASCO Annual Meeting found positive responses in patients with relapsed/refractory large B-cell lymphoma.

At the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, Julie M. Vose, MD, MBA, presented results from the pivotal phase 2 EPCORE NHL-1 trial (NCT03625037) that evaluated the efficacy of epcoritamab-bysp (Epkinly) alone in patients with relapsed/refractory B-cell lymphoma.

According to Vose, the treatment was able to elicit positive responses, especially in patients who were in remission 2 years after starting therapy. Even at 3 years, the trial found that 96% of patients remained in complete remission. The trial also had a patient population with less bulky disease, less amount of disease, and fewer treatments.

Vose is the George and Peggy Payne Distinguished Chair of Oncology, the chief of the Division of Oncology and Hematology, and a professor in the Division of Oncology and Hematology at the University of Nebraska Medical Center, and co-editor-in-chief of ONCOLOGY®.

Transcript:

The complete response rate was around 40%, and this analysis is a little bit different in that we’re looking at patients who were still in remission 2 years after initiating therapy. The subset analysis was to see what happened to those patients beyond the 2 years. At the 2-year mark for those patients who were in a complete remission, looking further at a 3-year time frame, 96% of those patients were still in complete remission, and had maintained that during that time period. This is a different type of analysis, looking at those long-term patients who benefited from the treatment.

These findings show that we do have alternatives for those patients now that are relatively well tolerated and have a high complete response rate. Those patients who are in a complete response tend to stay in complete response, if it’s molecularly, and by PET or other scanning, also negative. It’s a good alternative for those patients, and eventually they get down to less frequent dosing and toxicity after the first cycle is well tolerated. It’s a good alternative for those in certain patient populations.

The patients who were in complete response at 2 years, by analysis, tended to have less bulky disease, less amount of disease, and had received fewer prior therapies, so [they] were perhaps less resistant. That’s true in almost all our treatments. Those characteristics are true in any treatment that we do, so it’s not too surprising. [They] continued to be monitored long term.

Reference

Karimi YH, Vose JM, Clausen MR, et al. Novel analysis of 3-y results from the pivotal EPCORE NHL-1 study: Outcomes in patients (pts) with relapsed/refractory large B-cell lymphoma (R/R LBCL) and complete response (CR) at 2 y with epcoritamab (epcor) monotherapy. J Clin Oncol. 2025;43(suppl 16):7043. doi:10.1200/JCO.2025.43.16_suppl.7043

Recent Videos
Future findings from a translational analysis of the OVATION-2 trial may corroborate prior clinical data with IMNN-001 in advanced ovarian cancer.
The dual high-affinity binding observed with ISB 2001 may avoid resistance mechanisms reported with other BCMA-targeted therapies.
The use of chemotherapy trended towards improved recurrence-free intervals in older patients with high-risk tumors as determined via the MammaPrint assay.
Use of a pharmacist-directed resource appears to improve provider confidence and adverse effect monitoring for patients undergoing infusion therapy.
Reshma L. Mahtani, DO, describes how updates from the DESTINY-Breast09, ASCENT-04, and VERITAC-2 trials may shift practices in the breast cancer field.
Stage IV lung cancer may be curable based on the success of the DREAM Program, according to thoracic surgeon, Ankit Bharat, MBBS,
Ankit Bharat, MBBS, a thoracic surgeon, discussed potential treatment emergent adverse effects or complications, as well as strategies for managing them.
The Jack & Sheryl Morris Cancer Center offers “state-of-the-art” surgical suites and advanced radiation technology, says Andrew M. Evens, DO, MBA, MSc.
Related Content